Table 3.
Differences in treatment for inflammatory bowel disease between cases and controls.
| Variable | Cases n = 482 |
Controls n = 964 |
Univariate p-Value |
|---|---|---|---|
| 5ASA, n (%) | 204 (42) | 332 (34) | 0.003 |
| Oral (oral and topic) | 125 (26) | 180 (19) | <0.0001 |
| Topical (exclusive) | 6 (1) | 18 (1.9) | 0.051 |
| Monotherapy | 142 (29) | 214 (22) | 0.9 |
| Systemic steroids, n (%) | 26 (5.4) | 35 (3.6) | 0.06 |
| Immunosuppressants (all), n (%) | 319 (66) | 611 (63) | 0.39 |
| Immunosuppressants (in monotherapy), n (%) | 113 (23) | 191 (20) | |
| Azathioprine | 90 (19) | 160 (17) | |
| Mercaptopurine | 8 (1.7) | 7 (0.7) | |
| Cyclosporine | 1 (0.2) | 1 (0.1) | |
| Methotrexate | 9 (1.9) | 11 (1.1) | |
| Tacrolimus | 1 (0.2) | 2 (0.2) | |
| Tofacitinib | 4 (0.8) | 6 (0.6) | |
| Biologics (all), n (%) | 235 (49) | 493 (51) | 0.28 |
| Biologic (in monotherapy), n (%) | 117 (22) | 239 (25) | |
| Anti-TNF | 71 (15) | 134 (14) | |
| Vedolizumab | 25 (5.2) | 50 (5.2) | |
| Ustekinumab | 21 (4.3) | 52 (5.4) | |
| Combotherapy, n (%) | 59 (12) | 148 (15) | |
| Anti-TNF plus thiopurines | 37 (7.7) | 85 (8.8) | |
| Anti-TNF plus methotrexate | 9 (1.9) | 28 (2.9) | |
| Vedolizumab plus thiopurines | 5 (1) | 11 (1.1) | |
| Vedolizumab plus methotrexate | 1 (0.2) | 3 (0.3) | |
| Ustekinumab plus thiopurines | 5 (1) | 15 (1.6) | |
| Ustekinumab plus methotrexate | 2 (0.4) | 6 (0.6) |